A Phase 3 interventional study of Bendamustine and Chlorambucil in Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Completed at 174 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 6th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
BeOne Medicines · Sites in United States, Argentina, Australia and 18 more countries
Ages 18+
PETHEMA Foundation · Sites in Spain
Ages 18+
AbbVie · Sites in United States, Australia, France and 6 more countries
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 13
First in 2009; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 979 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 53 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 53 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one has the largest enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2013, is one of 10 in phase 3, and was the 29th registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
12 of the studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
| NCT04722172Memorial Sloan Kettering Cancer CenterA Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | 2027-02 |
Add all 12 to your calendar (.ics) → With an account.
Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide \[FC\], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
Drug: Bendamustine · Drug: Chlorambucil · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Obinutuzumab
Bendamustine: 90 milligram per millilitre square (mg/m\^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m\^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m\^2 in previously untreated participants, and bendamustine 50 mg/m\^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
Cyclophosphamide 250 mg/m\^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m\^2 p.o. QD Day 1-3 in fit participants only.
Fludarabine 25 mg/m\^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m\^2 per os (p.o.) QD Day 1-3 in fit participants only.
Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
Also known as: Gazyva®, RO5072759
Number of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).
Time frame: Baseline up to time of primary completion (3 years)
Number of Participants With Adverse Events of Special Interest (AESIs)
The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) "Infections and infestations" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.
Time frame: Baseline up to time of primary completion (3 years)
Number of Participants With Adverse Events of Particular Interest (AEPIs)
The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing "Hepatitis B" or "hepatitis acute", thrombocytopenia defined via Roche MedDRA basket subgroup "haematopoietic thrombocytopenia", second malignancies defined as AEs from the SOC "Neoplasms benign, malignant and unspecified" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ "Malignant or unspecified tumours", in which benign neoplasms are not included, Cardiac events including AEs from the SOC "Cardiac disorders", and hemorrhagic events defined via Roche MedDRA basket subgroup "Haemorrhagic events". Reported are number of participants with total AEPIs and each of the AEPI categories.
Time frame: Baseline up to time of primary completion (3 years)
Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA)
OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
Time frame: 3 months after the last dose of study treatment (up to approximately 5 years)
Percentage of Participants With Minimal Residual Disease (MRD)-Negativity as Assessed by Flow Cytometry
MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment \[FRA\] visit).
Time frame: 3 months after the last dose of study treatment (up to approximately 5 years)
Percentage of Participants With Best Overall Response (BOR)
BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Median Time to Progression-Free Survival (PFS)
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: \>/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.
Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Median Time to Response (TTR)
Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Median Time to Event-Free Survival (EFS)
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: \>/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.
Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
Median Time to Overall Survival (OS)
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.
Time frame: Baseline until death (Approximately up to 5 years)
Median Time to New Anti-Leukemia Therapy (TTNT)
Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.
Time frame: Baseline until end of study (up to approximately 5 years)
Median Time to Duration of Response (DoR)
Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.
Time frame: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
The study was conducted at 195 centers in 31 countries
| Milestone | Obinutuzumab |
|---|---|
| Started | 972 |
| Completed | 658 |
| Not completed | 314 |
| Withdrew: Withdrawal of consent | 90 |
| Withdrew: Lost to follow-up | 16 |
| Withdrew: Investigator discretion | 7 |
| Withdrew: Death | 186 |
| Withdrew: Adverse event | 3 |
| Withdrew: Other | 12 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs).
| Participants | Obinutuzumab |
|---|---|
| AEs | 950 |
| Grade 3-5 AEs | 780 |
| SAEs | 516 |
The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) "Infections and infestations" and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS.
| Participants | Obinutuzumab |
|---|---|
| Total AESIs | 905 |
| IRRs | 635 |
| Neutropenia | 599 |
| Infections | 521 |
| TLS | 62 |
The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing "Hepatitis B" or "hepatitis acute", thrombocytopenia defined via Roche MedDRA basket subgroup "haematopoietic thrombocytopenia", second malignancies defined as AEs from the SOC "Neoplasms benign, malignant and unspecified" starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ "Malignant or unspecified tumours", in which benign neoplasms are not included, Cardiac events including AEs from the SOC "Cardiac disorders", and hemorrhagic events defined via Roche MedDRA basket subgroup "Haemorrhagic events". Reported are number of participants with total AEPIs and each of the AEPI categories.
| Participants | Obinutuzumab |
|---|---|
| Total AEPIs | 467 |
| Thrombocytopenia | 314 |
| Cardiac events | 109 |
| Second malignancies | 82 |
| Second malignancies (SMQ) | 75 |
| Hemorrhagic events | 69 |
| Hepatitis B reactivation | 3 |
| PML | 1 |
OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
| percentage of participants | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Overall Response (OR) at Final Response Assessment (FRA) | 71.0 (52.0 to 85.8) | 59.4 (40.6 to 76.3) | 41.5 (29.4 to 54.4) | 83.9 (77.5 to 89.1) | 81.6 (75.1 to 87.0) | 73.2 (66.3 to 79.3) | 90.0 (83.8 to 94.4) | 84.6 (54.6 to 98.1) | 85.0 (70.2 to 94.3) | 100 (2.5 to 100.0) | 82.1 (70.8 to 90.4) | 56.5 (41.1 to 71.1) |
MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment \[FRA\] visit).
| percentage of participants | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood | 8.3 | 23.1 | 4.1 | 63.1 | 65.3 | 39.8 | 72.0 | 58.3 | 51.5 | — | 9.4 | 6.3 |
| Bone Marrow | 4.2 | 3.8 | 2.0 | 31.5 | 27.2 | 14.9 | 40.0 | 41.7 | 24.2 | — | 5.7 | 3.1 |
BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
| percentage of participants | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Best Overall Response (BOR) | 83.9 (66.3 to 94.5) | 71.9 (53.3 to 86.3) | 60.0 (47.1 to 72.0) | 91.7 (86.4 to 95.4) | 93.9 (89.3 to 96.9) | 86.8 (81.2 to 91.3) | 97.1 (92.8 to 99.2) | 84.6 (54.6 to 98.1) | 97.5 (86.8 to 99.9) | 100 (2.5 to 100.0) | 94.0 (85.4 to 98.3) | 84.8 (71.1 to 93.7) |
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: \>/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to Progression-Free Survival (PFS) | 43.0 (17.0 to NA) | 21.2 (14.9 to NA) | 17.6 (12.5 to 20.0) | 58.0 (44.5 to 58.0) | NA (45.4 to NA) | 28.6 (24.2 to 31.1) | NA (53.7 to NA) | NA (19.0 to NA) | 24.8 (19.3 to 35.0) | 31.3 (NA to NA) | 31.8 (27.7 to 36.4) | 14.1 (10.8 to 22.1) |
Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to Response (TTR) | 3.6 (3.2 to 3.8) | 3.6 (3.3 to 3.9) | 3.9 (3.7 to 4.4) | 3.5 (3.4 to 3.6) | 3.5 (3.5 to 3.7) | 3.7 (3.5 to 3.7) | 3.6 (3.5 to 3.7) | 4.1 (3.3 to 7.9) | 3.6 (3.4 to 3.7) | 3.3 (NA to NA) | 3.6 (3.4 to 3.7) | 3.7 (3.5 to 3.8) |
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: \>/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, \>/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, \>/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to Event-Free Survival (EFS) | 35.2 (15.6 to NA) | 17.9 (14.5 to NA) | 14.0 (9.1 to 17.9) | 58.0 (44.5 to 58.0) | 52.9 (44.7 to NA) | 25.1 (21.0 to 30.4) | NA (53.7 to NA) | NA (17.8 to NA) | 24.2 (18.7 to 33.8) | 31.3 (NA to NA) | 31.8 (27.7 to 36.4) | 13.7 (10.5 to 18.0) |
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to Overall Survival (OS) | NA (NA to NA) | NA (40.7 to NA) | NA (42.1 to NA) | NA (NA to NA) | NA (NA to NA) | NA (55.3 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (35.2 to NA) |
Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to New Anti-Leukemia Therapy (TTNT) | NA (25.0 to NA) | NA (27.5 to NA) | 22.5 (14.8 to 27.0) | NA (53.5 to NA) | NA (NA to NA) | 38.3 (31.5 to 42.0) | NA (NA to NA) | NA (35.0 to NA) | 32.6 (28.2 to NA) | NA (NA to NA) | 53.7 (37.1 to NA) | 20.4 (13.7 to 43.3) |
Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: \>/= 50% decrease in peripheral blood lymphocyte count AND \>/= 50% reduction in lymphadenopathy OR \>/= 50% reduction of liver enlargement OR \>/= 50% reduction of spleen PLUS one of the following: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L OR \>/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils \>1,500/mcL, platelets \> 100,000/mcL, hemoglobin \> 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure.
| months | G Mono: Previously Untreated Fit | G Mono: Previously Untreated Unfit | G Mono: Relapsed/Refractory | G-Benda: Previously Untreated Fit | G-Benda: Previously Untreated Unfit | G-Benda: Relapsed/Refractory | G-FC: Previously Untreated Fit | G-FC: Previously Untreated Unfit | G-FC: Relapsed/Refractory | G-Clb: Previously Untreated Fit | G-Clb: Previously Untreated Unfit | G-Clb: Relapsed/Refractory |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median Time to Duration of Response (DoR) | 40.1 (26.3 to NA) | 20.1 (12.1 to NA) | 15.0 (12.1 to 19.9) | 55.0 (44.2 to 55.0) | 49.3 (44.2 to NA) | 25.5 (21.2 to 29.7) | NA (50.1 to NA) | NA (48.3 to NA) | 21.2 (15.1 to 32.1) | 28.1 (NA to NA) | 28.1 (24.3 to 34.8) | 12.3 (7.3 to 20.6) |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-Mono | — | 71/127 (55.9%) | 108/127 (85%) |
| G-Benda | — | 335/537 (62.4%) | 503/537 (93.7%) |
| G-FC | — | 107/193 (55.4%) | 184/193 (95.3%) |
| G-Clb | — | 66/114 (57.9%) | 107/114 (93.9%) |
| Event | G-Mono | G-Benda | G-FC | G-Clb |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 12/127 | 65/537 | 15/193 | 17/114 |
| NeutropeniaBlood and lymphatic system disorders | 9/127 | 62/537 | 28/193 | 6/114 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/127 | 43/537 | 20/193 | 3/114 |
| PyrexiaGeneral disorders | 4/127 | 23/537 | 11/193 | 2/114 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 2/127 | 30/537 | 3/193 | 3/114 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/127 | 17/537 | 6/193 | 5/114 |
| Cytokine release syndromeImmune system disorders | 5/127 | 1/537 | 2/193 | 0/114 |
| Lung infectionInfections and infestations | 0/127 | 5/537 | 7/193 | 2/114 |
| DeathGeneral disorders | 2/127 | 7/537 | 1/193 | 4/114 |
| Anaphylactic reactionImmune system disorders | 4/127 | 1/537 | 0/193 | 0/114 |
| Event | G-Mono | G-Benda | G-FC | G-Clb |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 45/127 | 288/537 | 138/193 | 58/114 |
| NauseaGastrointestinal disorders | 23/127 | 144/537 | 75/193 | 26/114 |
| ThrombocytopeniaBlood and lymphatic system disorders | 27/127 | 162/537 | 67/193 | 34/114 |
| PyrexiaGeneral disorders | 28/127 | 173/537 | 61/193 | 28/114 |
| AnaemiaBlood and lymphatic system disorders | 19/127 | 134/537 | 50/193 | 27/114 |
| VomitingGastrointestinal disorders | 9/127 | 68/537 | 44/193 | 15/114 |
| FatigueGeneral disorders | 7/127 | 71/537 | 19/193 | 23/114 |
| DiarrhoeaGastrointestinal disorders | 6/127 | 83/537 | 38/193 | 11/114 |
| ChillsGeneral disorders | 18/127 | 92/537 | 30/193 | 19/114 |
| AstheniaGeneral disorders | 8/127 | 48/537 | 30/193 | 14/114 |
The intent-to-treat (ITT) population was defined as all participants enrolled in the study regardless of whether or not they received any study drug.
| Age, Continuous(years) | Obinutuzumab |
|---|---|
| Mean | 65.4 ± 10.94 |
| Sex: Female, Male(Participants) | Obinutuzumab |
|---|---|
| Female | 355 |
| Male | 617 |
Showing the first 100 of 174 sites across 31 countries. Choose a country and city above to see the rest.
Ran from Nov 2013 to primary completion in Dec 2016, 37 months.
Results were first posted in Oct 2018, 1 year 10 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 37 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →